|
The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: ---------- Symphony International Holdings Ltd - Asia-focused investment company focusing on healthcare, hospitality, lifestyle, logistics and education sectors - Reports net asset value attributable to ordinary shares at December 31 of 85.68 US cents, up slightly from 85.33 cents a year earlier. Profit before investment results and income tax falls sharply to $1.1 million from $37.9 million. The company says the full implications of the conflict involving Iran remain uncertain, particularly for oil prices, shipping routes and Asian growth. Still, it notes favourable long-term fundamentals in core markets including India, Vietnam and Thailand, and highlights Vietnam’s supportive logistics outlook. Symphony adds it remains committed to its orderly portfolio realisation strategy, though elevated global uncertainty has slowed transaction timelines for some larger assets. ---------- Cornish Metals PLC - mineral exploration and development company focused on the South Crofty tin mine in Cornwall, England - Reports a pretax loss widened to £8.6 million in 2025 from £1.7 million a year prior, as it continues to invest in advancing its South Crofty project. The company says preparatory work for a debt and equity financing package is ‘well underway’, which will be required to support development ahead of a final investment decision expected in 2026. Cornish Metals notes it raised £57.4 million during the year, while progressing dewatering, shaft refurbishment and early construction works at South Crofty, alongside advancing engineering and procurement activities. It adds that tin market fundamentals remain supportive, with strong prices underpinning the project’s long-term attractiveness as it moves towards production. ---------- Beacon Rise Holdings PLC - acquisition company - Reports a widened pretax loss of £694,061 for 2025 from £248,566 a year prior, as costs rose amid progress on its acquisition strategy. Says it has moved into the pre-execution phase of potential acquisitions, having advanced discussions and due diligence on a number of targets, with plans to complete transactions in 2026. The company intends to transition into an operating business and pursue an AIM listing, with head of terms agreed for three targets in physiotherapy, chiropractic and healthcare education. Beacon Rise adds it will continue to strengthen governance and financial resources as it executes its strategy, while managing increased operating costs linked to advisory fees and expansion. ---------- McBride PLC - Manchester, England-based private-label products manufacturer - Proposes the acquisition of Eurotab Group for €40 million in cash. The purchase would ‘further strengthen McBride’s position as a leading detergent producer in Europe’, it adds. It will be earnings accretive in the first full year of ownership. McBride adds that to date it has seen only a ‘relatively small impact on trading activities’ from the Middle East conflict. However, this is beginning to change as chemical and packaging suppliers implement price hikes. ‘The first signs of possible shortages in supply chains around the world are beginning to emerge. As a result, the group will see elevated input costs in April and expects further increases in the near future. Consequently, the group has already informed all customers about temporary price adjustments, or surcharges to current pricing, to recover these higher, beyond our control, cost impacts from the Middle East conflict,’ it adds. ---------- Tanfield Group PLC - passive investing company with 49% interest in producer of self-propelled, towable and push-around aerial lifts Snorkel International - Reports no revenue for 2025, unchanged year-on-year, and a widened pretax loss of £1.8 million from £403,000, driven by higher costs linked to ongoing US legal proceedings. Maintains valuation of its 49% stake in Snorkel International at £19.1 million, with US court rulings confirming its contractual position and that Snorkel owes a priority amount and preferred return following a call option exercise. Notes the only outstanding issue is the option price, with a jury trial expected after summer 2026, while cash and short-term deposits totalled £3.6 million at year-end. ---------- Firering Strategic Minerals PLC - Zambia and Ivory Coast-focused mining company - Reports Kiln 2 discharge at its Limeco project in Zambia has increased to over 70 tonnes per day from over 60 tonnes a fortnight ago. Improved output follows February commissioning and supports ongoing ramp-up, with the company citing stronger confidence in scaling production across the remaining kilns. Chair & Interim CEO Youval Rasin says: ‘Kiln 2 discharge is now at over 70 tonnes per day compared to an average of over 60 tonnes per day a fortnight ago, reflecting solid operational progress and setting a clear benchmark for the remaining kilns as we scale production at Limeco.’ ---------- Trellus Health PLC - London-based healthcare company - Secures $50,000 unsecured loan from Chief Executive Officer & Co-Founder Marla Dubinsky, with a 12-month term and 5% annual interest. Proceeds extend cash runway into late April 2026, while the company continues discussions on further funding options. The loan is treated as a related party transaction, with independent directors deeming terms fair and reasonable. ---------- Adnams PLC - Appointment of Chair Appoints Simon Townsend as chair with immediate effect, having served as interim chair since 2024. Townsend joined the board in January 2023 and remains a non-executive director and chair of the remuneration committee. Chief Executive Officer Jenny Hanlon notes Townsend has provided guidance during challenging trading conditions, while Townsend says: ‘Since my appointment as interim chair I have been fully committed to securing the long-term financial solution we need to support our growth.’ ---------- PureTech Health PLC - Boston, Massachusetts-based biotech and pharmaceutical firm - Reports positive phase 1 topline data from Seaport Therapeutics’ GlyphAgo candidate for generalised anxiety disorder, showing a 6.8-fold increase in bioavailability and good tolerability, with plans to advance into phase 2 trials. Separately, notes publication of phase 2b Elevate trial results for deupirfenidone in idiopathic pulmonary fibrosis, showing statistically significant slowing of lung function decline, as its founded entity Celea Therapeutics prepares to initiate a phase 3 trial in the first half of 2026. ---------- Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
